NCT01685281已完成2 期
Randomized, Double-blind, Single-center, Dose-finding Study Designed to Compare Two Doses of MG01CI (Metadoxine Extended Release) and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Alcobra Ltd.
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Change in TOVA ADHD score from Screening/Baseline to 4 hours post-dose;
研究概览
简要总结
study objectives are to compare the efficacy, safety and tolerability of two doses of MG01CI (1400 mg and 700 mg) to Placebo for the treatment of symptoms in adults diagnosed with PI-ADHD.
subjects will be randomly assigned in a 1:1:1 ratio to one of three treatment sequences as follows:
- week 1:1400 mg, week 2:700 mg, week 3:placebo
- week 1:700 mg,week 2: placebo,week 3:1400 mg
- week 1: placebo, week2:1400 mg, week 3 700 mg
The study will consist of three periods: a screening period of up to one week, a 3-week double-blind treatment period, and a one-week safety follow-up period.
详细描述
The purpose of this dose finding study is to compare two doses of MG01CI (1400 mg and 700 mg) to Placebo, in adult subjects with PI-ADHD. A crossover study design will allow evaluation of safety/tolerability and efficacy using validated computerized tests.
subjects will be randomly assigned in a 1:1:1 ratio to one of three treatment sequences as follows:
- week 1:1400 mg, week 2:700 mg, week 3:placebo
- week 1:700 mg,week 2: placebo,week 3:1400 mg
- week 1: placebo, week2:1400 mg, week 3 700 mg
Overview of Study Visits
Screening Period:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult men and women, 18 to 55 years old
- •Diagnosed with predominantly inattentive ADHD based on DSM-IV criteria for ADHD as assessed by the Adult ADHD Clinician Diagnostic Scale (ACDS V1.2);
- •Clinical severity of at least a moderate level (Clinical Global Impression score of 4 or above)
- •TOVA ADHD score of -1.8 or below at Screening /Baseline
- •Women with childbearing potential must agree to use effective contraceptive and have negative urine pregnancy test at screening visit
- •Able to attend the clinic regularly and reliably
- •Able to swallow tablets/capsules
- •Able to understand, read, write and speak Hebrew fluently to complete study related materials
- •Able to understand and sign written informed consent to participate in the study
排除标准
- •Subjects with ADHD not otherwise specified (NOS) diagnosis
- •Subjects with combined type or predominantly hyperactive impulsive ADHD diagnoses
- •Subjects with current Axis I diagnosis on SCID
- •Subjects with lifetime bipolar or psychosis
- •Subjects in treatment for Axis I disorders, even if the disorder is remitted
- •Subjects who were non-responders to at least two adequately administered ADHD treatments
- •Subjects with any medical or psychiatric condition common diseases such as hypertension, type 2 diabetes mellitus, hyperlipidemia, etc. are allowed per the Investigator's judgment, as long as they are stable and controlled by medical therapy that is constant for at least 8 weeks prior to randomization and throughout the study
- •Any prescription or non-prescription ADHD medications during the 14 days (for stimulants) or 28 days (for non-stimulants and other psychotropics) prior to the screening visit
- •Known or suspected HIV-positive or with advanced diseases such as AIDS, Hepatitis C, Hepatitis B or tuberculosis
- •History of allergy or sensitivity to B complex vitamins
- •History or suspicion of PDD, NLD or other psychotic conditions
- •Use of Vitamin B throughout the study (either alone or in any multi-vitamin)
- •Use of ADHD medications throughout the study
- •Use of any psychotropic medications throughout the study
- •Use of investigational medication/treatment in the past 30 days prior to the screening visit
- •Use of any medication or food supplement unless cleared by the medical monitor during the 14-day period before randomization
- •Current (or history within the last 6 months) of drug dependence or substance abuse disorder according to DSM-IV-TR criteria (excluding nicotine). Subjects should also agree to refrain from significantly changing consumption of caffeine during the study.
- •Suicidality, defined as active ideation, intent or plan, or any lifetime attempt (CSSRS)
- •Subjects who cannot complete any study instruments or questionnaires
- •Any relation to the Sponsor, Investigator or study staff
- •Any condition, which in the opinion of the Principal Investigator would place the subject at risk or influence the conduct of the study or interpretation of results, including (but not limited to) abnormally low intellectual capacity.
- •Subjects who cannot fully comprehend the implications of the protocol or comply with its requirements or are capable to follow the study schedule for any reason
- •Women of childbearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test and agree to use a reliable method of birth control (e.g., oral contraceptives or Norplant®; a reliable barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam]; intrauterine devices; partner with vasectomy; or abstinence) during the study. Note that this inclusion criterion applies only to females of childbearing potential. Females of childbearing potential are defined as women not surgically sterilized and between menarche and 2 years post-menopause
研究组 & 干预措施
Metadoxine (MG01CI) 1400 mg
Active Comparator
single dose of Metadoxine (MG01CI) 1400 mg
干预措施: Metadoxine (MG01CI) (Drug)
Metadoxine (MG01CI) 700 mg
Active Comparator
Single dose of Metadoxine (MG01CI) 700 mg
干预措施: Metadoxine (MG01CI) (Drug)
Placebo
Placebo Comparator
Single dose of Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Change in TOVA ADHD score from Screening/Baseline to 4 hours post-dose;
时间窗: 4 weeks
TOVA® is a computerized test that provides information about an individual's sustained attention, speed and consistency of responding, and behavioral self-regulation and executive functioning
次要结局
- Change in CANTAB sub-scores from baseline (Visit 2) to 4 hours post-dose;(4 weeks)
- Change in TOVA sub-scores from Screening/Baseline to 4 hours post-dose(4 weeks)
- Number of participants who withdrew early from the study due to AE(5 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Meloxicam SoluMatrix® Capsules vs Meloxicam Tablets to Treat Osteoarthritis PainOsteoarthritisNCT02405793Iroko Pharmaceuticals, LLC
已完成
1 期
BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered AloneHealthyNCT01595880LG Life Sciences29
撤回
2 期
Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant EpilepsiesResistant Epilepsy, DrugAdolescent EpilepsyChildren EpilepsyChildren and Adolescents With Resistant EpilepsiesNCT04406948MGC Pharmaceuticals d.o.o
已完成
1 期
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy VolunteersHealthy VolunteersNCT03792308Spero Therapeutics94
已完成
1 期
To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male SubjectsHealthy VolunteersNCT03390673Prestige Biopharma Limited119